1. Home
  2. NEOV vs MDWD Comparison

NEOV vs MDWD Comparison

Compare NEOV & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoVolta Inc.

NEOV

NeoVolta Inc.

HOLD

Current Price

$3.43

Market Cap

129.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.77

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOV
MDWD
Founded
2018
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.2M
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NEOV
MDWD
Price
$3.43
$18.77
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
232.3K
96.8K
Earning Date
11-10-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,486,857.00
$20,932,000.00
Revenue This Year
$148.14
$15.89
Revenue Next Year
$6.34
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
486.23
6.15
52 Week Low
$1.80
$14.14
52 Week High
$6.19
$22.51

Technical Indicators

Market Signals
Indicator
NEOV
MDWD
Relative Strength Index (RSI) 40.26 55.27
Support Level $3.35 $18.71
Resistance Level $3.93 $19.40
Average True Range (ATR) 0.32 0.63
MACD -0.02 0.14
Stochastic Oscillator 15.29 65.02

Price Performance

Historical Comparison
NEOV
MDWD

About NEOV NeoVolta Inc.

NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: